# Neos Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neos-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Grand Prairie, US
- Website: www.neostx.com
- Total disclosed funding: $18M
- Latest round: Series C (Jul 16, 2012)
- Investors on record: 5

## About

Neos Therapeutics, Inc. specializes in developing and commercializing therapeutics for central nervous system disorders, focusing on enhancing cognitive function through innovative treatment options for conditions such as ADHD and major depressive disorder.Founded in 2008 and headquartered in Grand Prairie, US, Neos Therapeutics, Inc. is dedicated to providing advanced therapeutic solutions. The company recently underwent a merger with Aytu BioScience, Inc. expected to finalize in 2021. The CEO, Vipin Garg, leads the company in its mission to improve patient outcomes. Neos has successfully raised USD 40.00 mn in its latest funding round, contributing to a total amount raised of USD 40.00 mn through various funding rounds including a notable IPO in July 2015 generating USD 72 mn.Neos Therapeutics focuses on developing innovative therapeutics aimed at improving the quality of life for patients with central nervous system conditions. Their premier product, EXXUA™, is designed for the treatment of ADHD, employing unique mechanisms to improve cognitive function and emotional regulation. The company markets its products to healthcare providers, clinics, and hospitals, directly impacting the treatment of patients diagnosed with CNS disorders across North America and exploring opportunities for international market expansion.In the most recent year, 2019, Neos Therapeutics reported a revenue of USD 64.65 mn and an EBITDA of USD -6.22 mn. Revenue generation primarily occurs through direct sales of pharmaceutical products to healthcare providers and institutions, with an emphasis on ensuring access to their therapeutic offerings.Neos Therapeutics plans to leverage recent funding to support the development of upcoming products and expand into new markets. The company aims to introduce additional therapeutic options for ADHD and other CNS disorders, with releases targeted in the coming years. The merger with Aytu BioScience is expected to enhance market reach and operational capabilities, with the goal of accessing new geographical regions and enhancing product distribution to improve patient access.

## Funding rounds

- Series C, Jul 16, 2012, $18M — Burrill & Company, Presidio Partners, Crabtree Ventures, CAC, LLC, Delaware Street Capital

## Investors

- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series C
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series C
- Crabtree Ventures — Series C
- CAC, LLC — Series C
- Delaware Street Capital — Series C